Collegium Reports Fourth Quarter Financial Results And Provides Corporate Update
CANTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the fourth quarter of 2016 and provided a corporate update.
“We have made significant progress on the commercial launch of Xtampza ER. Through mid-February, more than 2,400 physicians have prescribed Xtampza ER, including 800 first time prescribers in 2017 alone,” stated Michael Heffernan, Collegium’s CEO. “With broadened payer coverage and improved pharmacy availability, we are building a solid foundation for a successful commercial launch.”
“We have made significant progress on the commercial launch of Xtampza ER. Through mid-February, more than 2,400 physicians have prescribed Xtampza ER, including 800 first time prescribers in 2017 alone,” stated Michael Heffernan, Collegium’s CEO. “With broadened payer coverage and improved pharmacy availability, we are building a solid foundation for a successful commercial launch.”